Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Sunday. The firm issued a sell rating on the stock.

Separately, Dawson James assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a buy rating and a $3.00 price objective for the company.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $0.19 on Friday. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $3.31. The stock has a fifty day moving average price of $0.25 and a 200-day moving average price of $0.36. The company has a current ratio of 2.53, a quick ratio of 1.81 and a debt-to-equity ratio of 0.06. The firm has a market cap of $16.39 million, a PE ratio of -0.02 and a beta of 2.16.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The business had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.95 million. Equities research analysts predict that Tonix Pharmaceuticals will post -3.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals accounts for approximately 0.5% of Sabby Management LLC’s portfolio, making the stock its 6th biggest position. Sabby Management LLC owned approximately 7.02% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.